Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
复制标题
B细胞慢性淋巴细胞白血病患者在同种异体干细胞移植后出现微小残留病很常见，并且可能通过移植物抗宿主病得到控制
作者：
J. Mattsson;M. Uzunel;M. Remberger;P. Ljungman;E. Kimby;O. Ringdén;H. Zetterquist
在异基因干细胞移植(SCT)后，我们研究了在B细胞慢性淋巴细胞白血病(CLL)患者中CD19+B细胞部分中供者和受者来源细胞的存在。通过测序和使用来自克隆性重排免疫球蛋白重链(IgH)受体基因连接区的患者特异性引物，通过微小残留病(MRD)检测进一步调查6名患者的嵌合状态。到目前为止，6名患者中有5名在SCT后存活，中位随访时间为24个月(范围15-60)。所有患者都经历了急性和慢性移植物抗宿主病，并对SCT有临床反应。所有患者SCT后均为MRD阳性，除1例(25/26)外，其余患者均与CD19+细胞混合嵌合体有关。肿瘤坏死因子-α和可溶性白介素2受体(sIL-2R)的高水平预示着疾病的进展，而SCT前后水平升高的患者也是SCT后持续时间最长的α可检测的MRD的患者。因此，SCT前的高肿瘤负荷可能反映了SCT后B-CLL患者可检测到的MRD持续时间较长。持久的抗白血病作用可能对这些患者很重要。
Following allogeneic stem cell transplantation (SCT), we studied the presence of donor and recipient derived cells within the CD19+ B cell fraction, in patients with B cell chronic lymphocytic leukemia (CLL). The chimeric status of the six patients studied was further investigated with minimal residual disease (MRD) detection, by sequencing and using patient-specific primers derived from junctional regions of clonally rearranged immunoglobulin heavy-chain (IgH) receptor genes. To date, five of six patients are alive with a median follow-up time of 24 months (range 15–60) post-SCT. All patients experienced acute and chronic graft-versus-host disease and responded clinically to SCT. All patients were MRD positive after SCT, which correlated to mixed chimerism within the CD19+ cell fraction in all samples except one (25/26). High levels of tumor necrosis factor-α (TNF-α) and soluble interleukin-2 receptor (sIL-2R) indicated advanced disease, and patients with increased levels pre- and post-SCT were also those with the most long-lasting PCR-detectable MRD post-SCT. Hence, a high tumor burden pre-SCT may reflect the long duration of detectable MRD in patients with B-CLL after SCT. A durable anti-leukemic effect was probably important in these patients.
登录
查看更多内容
影响因子：
158.5
作者：
WEIDEN, PL;SULLIVAN, KM;THOMAS, ED
通讯作者：
THOMAS, ED
B 细胞慢性淋巴细胞白血病的正常细胞对应物。
影响因子：
20.3
作者：
Freedman,AS;Boyd,AW;Bieber,FR;Daley,J;Rosen,K;Horowitz,JC;Levy,DN;Nadler,LM
通讯作者：
Nadler,LM
影响因子：
20.3
作者：
Stephen Mackinnon;L. Barnett;Jean Bourhis;P. Black;G. Heller;R. O'reilly
通讯作者：
Stephen Mackinnon;L. Barnett;Jean Bourhis;P. Black;G. Heller;R. O'reilly
影响因子：
20.3
作者：
T. Miyashita;John Calvin Reed
通讯作者：
T. Miyashita;John Calvin Reed
影响因子：
158.5
作者：
STORB, R;DEEG, HJ;THOMAS, ED
通讯作者：
THOMAS, ED